Cannabis Products, Research and Development, Schedule I Drugs

Trump Signals Cannabis Rescheduling: Schedule III Marijuana Decision Expected Soon

Vicente LLP on 8/21/2025

Key Takeaways - • President Trump’s administration is actively reviewing a proposal to move cannabis from Schedule I to Schedule III of the federal Controlled Substances Act (CSA) and a decision on rescheduling is expected...more

FDA's View on Cannabis

Gardner Law on 4/3/2024

The U.S. Food and Drug Administration (FDA) is continuing to support clinical research for cannabis and psychedelic drug development. On the heels of publishing its first draft guidance on clinical trials involving...more

HHS Proposes Rescheduling Cannabis to Schedule III – What It Means for the Industry

Troutman Pepper Locke on 9/5/2023

It has been widely reported and confirmed publicly that, on August 29, the U.S. Department of Health and Human Services (HHS) sent a letter to the Drug Enforcement Administration (DEA) recommending that cannabis be moved from...more

Doctor-Patient Relationships and Medical Marijuana: Where Are We Now?

McDermott Will & Schulte on 12/29/2022

On December 2, 2022, President Joseph Biden signed the Medical Marijuana and Cannabidiol Research Expansion Act (Cannabis Research Act), which provides a mechanism for industry and academia to access and research cannabis,...more

MarkIt to Market® - October 2021: Watching the Pot™

Sterne, Kessler, Goldstein & Fox P.L.L.C. on 10/28/2021

DEA Calls for Increased Production Quotas for Research-Grade Cannabis and Psychedelics in 2022 - While it may come as a surprise to some, the U.S. Drug Enforcement Administration (DEA) has called for significantly...more

MarkIt to Market® - October 2021

Sterne, Kessler, Goldstein & Fox P.L.L.C. on 10/26/2021

The October 2021 issue of Sterne Kessler's MarkIt to Market® newsletter discusses a precedential TTAB decision regarding fraud; the DEA's proposal to increase production quotas for several schedule I controlled substances,...more